@entity1862 for recurrent surgery and radiation refractory XXXX : a retrospective case series.

@entity1 @entity137 @entity417 @entity1862 @entity1295 @entity1653
@entity1862 (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in @entity1 with surgically and radiation refractory @entity1653 based on a limited literature. A retrospective case series of 60 @entity1 with recurrent WHO grade 1 @entity1653 treated with HU following progression after surgery and radiotherapy was conducted with primary study objective progression free survival (PFS) at 6- and 12-months. Sixty @entity1 (45 @entity1 ; 15 @entity1 : median age 61.5  years, range 26-88) with recurrent @entity1653 were treated with HU (1000  mg/m(2)/day orally divided twice per day; one cycle operationally defined as 4-weeks of daily HU). All @entity1 had progressed radiographically after prior therapy with surgery (60/60) and radiotherapy (external beam radiotherapy 60/60; stereotactic radiotherapy 53/60). No @entity1 received prior chemotherapy or targeted therapy before instituting HU. @entity1 received 1-12 cycles (median 2.0) of HU with modest @entity137 (10% grade 3  +  @entity417 or @entity1295 ). There were no radiographic responses, 35% of @entity1 had stable disease and 65% manifested progressive disease. Duration of stable disease ranged from 3 to 12  months (median 4.0  months). The overall PFS was 10% (median PFS 2.0  months). The majority of @entity1 (80%) following progression on HU were subsequently treated on an investigational trial. In this retrospective case series, HU though generally well tolerated and convenient, appeared to have very limited activity which raises questions of what constitutes effective salvage therapy and indicates an unmet need for alternative treatments for recurrent @entity1653 .
